Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (AGL), MiMedx Group (MDXG) and Park Dental Partners, Inc. (PARK)

Tipranks - Fri Feb 27, 10:12AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilon Health (AGLResearch Report), MiMedx Group (MDXGResearch Report) and Park Dental Partners, Inc. (PARKResearch Report).

Claim 50% Off TipRanks Premium

Agilon Health (AGL)

Bank of America Securities analyst Michael Craig Jones maintained a Sell rating on Agilon Health today. The company’s shares closed last Thursday at $0.56.

According to TipRanks.com, Jones is ranked #3348 out of 12136 analysts.

Currently, the analyst consensus on Agilon Health is a Hold with an average price target of $0.84, implying a 69.7% upside from current levels. In a report released today, TipRanks – Google also downgraded the stock to Sell with a $0.47 price target.

See today’s best-performing stocks on TipRanks >>

MiMedx Group (MDXG)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on MiMedx Group today. The company’s shares closed last Thursday at $4.87.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 33.9% and a 59.6% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $9.60 average price target, implying an 83.2% upside from current levels. In a report issued on February 23, Citizens JMP also initiated coverage with a Buy rating on the stock with a $10.00 price target.

Park Dental Partners, Inc. (PARK)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Park Dental Partners, Inc.. The company’s shares closed last Thursday at $19.97, close to its 52-week high of $21.60.

According to TipRanks.com, Hewitt has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.8% and a 35.5% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Dyadic International, and InfuSystem Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Park Dental Partners, Inc. with a $21.50 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.